| Literature DB >> 30257423 |
Ali H El-Far1, Soad K Al Jaouni2, Weikun Li3, Shaker A Mousa4.
Abstract
The focus on nanotechnology for improved bioavailability and drug delivery is of increasing importance for control of different human diseases. Therefore, numerous nanoformulations have been developed for the oral bioavailability of different drugs. This review introduces applications of nanomedicine to enhance the biological activities of thymoquinone (TQ) to control different diseases in several in vivo studies as a preliminary investigation for human disease treatment with nano-TQ. Nano-TQ effectively augments the anticancer roles of doxorubicin by upregulation of P53 and downregulation of Bcl2 and potentiates paclitaxel's apoptosis in MCF-7 breast cancer cells. Moreover, nano-TQ protects against diabetes, inflammation, CNS, and hepatotoxicity, mainly by enhancement of organs' antioxidant status. We summarize the pros and cons of several FDA approved nanoparticle-based therapeutics and discuss the roadblocks in clinical translation, along with potential nano-TQ strategies to overcome these roadblocks. From this review, we can conclude that nano-TQ may be considered as a promising nutraceutical for human health.Entities:
Keywords: biological activities; human diseases control; nanoformulation; thymoquinone
Mesh:
Substances:
Year: 2018 PMID: 30257423 PMCID: PMC6213571 DOI: 10.3390/nu10101369
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Biological activities of thymoquinone.
Figure 2Advantages of thymoquinone nanoformulations.
TQ and TQ nanoformulations and characteristics.
| Method | Materials, Stabilizer | Size (nm) | Animal, Dose | Therapeutic Effect | Reference |
|---|---|---|---|---|---|
| Single emulsion | PLGA | 200~300 | Enhanced anticancer activity | [ | |
| Compritol ATO 888, gelucire | ~200 | Rats, 20 mg/kg, oral | 4-Fold enhancement of oral bioavailability | [ | |
| Double emulsion | Poly- | 185 | Mice, ~150 mg/kg, subcutaneous injection | Inhibited tumor growth 43%, 31% | [ |
| Nano-precipitate | PVP, PEG200, PEG4000, P123 | 20~40 | Mice, 5 mg/kg, subcutaneous injection | Reduced tumor and increased lifespan | [ |
| Gum rosin, oleic acid, PVA, polysorbate 80 | 50–90 | Wistar female albino rats, 20, 40, 80 mg/kg, oral | Significantly decreased blood glucose level and glycated hemoglobin | [ | |
| Ionic gelation | Chitosan, TPP | 150 | Male Wistar rats, 2.52 mg/kg, intranasal | 15-Fold higher brain targeting efficiency | [ |
| Film rehydration | Liposomes | 100 | More potent anti-proliferative activity | [ | |
| Cold wet-milling | HPC-SSL | 143 | Male Sprague-Dawley rats, 2 mg/kg, oral | 6-Fold enhancement of oral bioavailability | [ |
Abbreviations: PLGA, poly(d,l-lactide-co-glycolide); PVA, poly(vinyl alcohol); PVP, polyvinylpyrrolidone; PEG, poly(ethylene glycol); P123, poly(ethylene glycol)-b-poly(propylene glycol)-b-poly(ethylene glycol); TPP, sodium triphosphate; HPC-SSL, hydroxypropyl cellulose grade SSL.
Figure 3Thymoquinone nanoformulations prepared through (a) single emulsion; (b) double emulsion; (c) nanoprecipitation; (d) ionic gelation methods.
Figure 4Biological activities of thymoquinone nanoformulations. ALP, alkaline phosphatase; Bcl2, B-cell lymphoma 2; DOX, doxorubicin; GPx, glutathione peroxidase; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein-cholesterol; IL, interleukin; LDL-C, low-density lipoprotein-cholesterol; PTX, paclitaxel; SGOT, serum glutamate oxaloacetate transaminase; SGPT, serum glutamate pyruvate transaminase; SOD1, Copper, zinc-dependent superoxide dismutase (cytosolic); SOD2, manganese-dependent superoxide dismutase (mitochondrial); SOD3, Copper, zinc-dependent superoxide dismutase (extracellular); TAG, triacylglycerol; TNF-α, tumor necrosis factor-α; TQ, thymoquinone; VLDL-C, very low-density lipoprotein-cholesterol.
Figure 5(a) Scanning electron microscope (SEM) and (b) transmission electron microscope (TEM) images of TQ/PLGA nanoparticles formulated with single emulsion solvent evaporation method. Reprinted with permission from Ref. [18].
Figure 6Nano-TQ and its uses in health and nutrition.
Critical parameters for scale-up or GMP manufacturing of nanomedicine technology for nano-TQ.
| Thermal Stress | Complexity | Scale-Up Principle | Organic Solvent | |
|---|---|---|---|---|
| Ball Mill Emax (wet milling) | Yes | >50 cycles | Top-down | No |
| Microfluidizer® | No | 5–6 cycles | Bottom-up (single emulsion) | Yes |
| NanoAssemblr™ | No | 1-step | Bottom-up (nano-precipitate) | Yes |
| MicroJet Reactor (MJR®) | No | 1-step | Bottom-up (nano-precipitate) | Yes |
| Nano Spray Dryer B-90 (spray-drying) | No | 1-step | Bottom-up (freeze-dry) | Yes |